BRIDGEWATER, N.J. and
NEW YORK, July 17, 2019 /CNW/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company")
and Progenics Pharmaceuticals (NASDAQ: PGNX), announced today that
the U.S. District Court of New
Jersey upheld the validity and determined Actavis'
infringement of a patent protecting RELISTOR® (methylnaltrexone
bromide) tablets, expiring March
2031.
Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva
Pharmaceutical Industries Ltd, had challenged the validity of and
had alleged non-infringement of Claims 2 and 5 of U.S. Patent No.
8,524,276, which protects the formulation of RELISTOR® tablets.
Bausch Health is not aware of any other ANDAs filed with the FDA
seeking approval of a generic version of RELISTOR tablets, and will
continue to vigorously defend its intellectual property in these
and other claims.
About Progenics
Progenics is an oncology company
focused on the development and commercialization of innovative
targeted medicines and artificial intelligence to find, fight and
follow cancer, including: therapeutic agents designed to treat
cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane
antigen ("PSMA") targeted imaging agents for prostate cancer (PyL™
and 1404); and imaging analysis technology (aBSI and PSMA AI).
Progenics has two commercial products, AZEDRA, for the treatment of
patients with unresectable, locally advanced or metastatic
pheochromocytoma or paraganglioma (rare neuroendocrine tumors of
neural crest origin) who require systemic anticancer therapy; and
RELISTOR® (methylnaltrexone bromide) for the treatment of
opioid-induced constipation, which is partnered with Bausch Health
Companies Inc.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may
generally be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"will," "believes," "estimates," "potential," "target," or
"continue" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties discussed in the
Company's most recent annual or quarterly report and detailed from
time to time in the Company's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. In addition,
certain material factors and assumptions have been applied in
making these forward-looking statements, including that the risks
and uncertainties outlined above will not cause actual results or
events to differ materially from those described in these
forward-looking statements. The Company believes that the material
factors and assumptions reflected in these forward-looking
statements are reasonable, but readers are cautioned not to place
undue reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Bausch
Health undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
Investor/Media Contact:
Arthur Shannon
arthur.shannon@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/court-upholds-the-validity-and-determined-actavis-infringement-of-patent-protecting-relistor-tablets-300887079.html
SOURCE Bausch Health Companies Inc.